Lilly signs oncology collaboration with Stipple Bio worth up to $5.9 billion
Life Sciences
Monday, November 16, 2026
- Updated Nov 16, 2026 16:47
Eli Lilly has entered a multi-target, multi-modality research collaboration and licence agreement with Cambridge, Massachusetts based Stipple Bio that could pay Stipple up to $5.9 billion in milestone payments plus tiered royalties.
Why it matters: The deal is Lilly's second oncology transaction of the day and, on Endpoints News' count, its second-largest collaboration this year by total value, extending a buying and licensing run funded by its GLP-1 sales.
Data as of Stipple Bio announcement of November 16, 2026 and Endpoints News reporting of the same day. The Endpoints article itself is paywalled beyond its opening lines; the deal terms stated here were verified on a second route, Stipple's own announcement of a strategic research collaboration and license agreement and the Reuters-carried release summary, which give the upfront payment and equity investment, Lilly's exclusive worldwide development and commercialisation rights, and up to $5.9 billion in aggregate milestone payments plus tiered royalties. Developing item.
Eli Lilly has entered a strategic research collaboration and licence agreement with Stipple Bio, a Cambridge, Massachusetts startup, to develop new cancer treatments across multiple targets and modalities, the companies said on Monday. Stipple will use its Pointillist Platform to discover tumour-specific cell surface epitope binders, which Lilly will combine with its own oncology technologies, and Lilly gains exclusive worldwide development and commercialisation rights.
Stipple receives an upfront payment and an equity investment, and could receive up to $5.9 billion in aggregate milestone payments plus tiered royalties on sales, making this, on Endpoints News’ count, Lilly’s second-largest collaboration this year by total deal value. The agreement is Lilly’s second oncology deal announced on Monday, after its agreement to acquire Calytrix Bio for up to $1.5 billion, covered separately in this edition.
Sources
- Lilly strikes up to $5.9B cancer deal with Stipple Bio - Endpoints News - 2026-11-16
- Stipple Bio enters multi-target oncology collaboration with Eli Lilly - Reuters, via TradingView - 2026-11-16
- Stipple Bio announces strategic research collaboration and license agreement with Eli Lilly and Company - Stipple Bio, via LinkedIn - 2026-11-16